Thermo Fisher Scientific posted second-quarter adjusted EPS of $6.03, clearing the $5.72 Wall Street consensus by a solid margin and representing roughly 13% growth year over year. Revenue for the quarter ended June 27, 2026, came in at $11.99 billion, up 10% from $10.85 billion a year earlier and well ahead of the $11.71 billion analysts had penciled in.
The Laboratory Products and Biopharma Services segment did the heavy lifting, generating $6.69 billion, about 55.8% of total revenue and roughly 12% higher than the same quarter last year. Life Sciences Solutions added $2.8 billion, up around 13%, while Analytical Instruments contributed $1.8 billion, a gain of about 7%. Organic revenue across the company grew 5% year over year.
Adjusted operating margin expanded to 22.8% from 21.9% in the prior-year period. GAAP diluted EPS rose 9% to $4.68, and GAAP operating margin came in at 17.4%, up 50 basis points year over year.
Guidance Lifted Across the Board
Management raised its full-year 2026 adjusted EPS guidance to a range of $24.93 to $25.33, up from the prior $24.64 to $25.12, nudging past the $24.85 consensus. Revenue guidance moved to $47.4 billion to $48.1 billion from $47.3 billion to $48.1 billion, with the midpoint now sitting above the $47.76 billion analysts had expected. CEO Marc Casper said the company is "well positioned to deliver a great 2026" at the halfway point of the year.
During the quarter Thermo Fisher bought back $1.0 billion of its own stock and announced plans to divest its microbiology business. The company also launched next-generation Orbitrap platforms with AI-driven analytics and opened a new Bioprocess Design Center in Plainville, Massachusetts.
Context: Danaher's Weak Outlook Had Rattled the Sector
The strong print carries extra weight after peer Danaher flagged a soft Q3 outlook earlier in the week, sending jitters through life-sciences stocks. Thermo Fisher's beat lands as a direct counter-signal. The week's volatility is a reminder of how quickly sector sentiment can swing on a single earnings report, not unlike the sharp moves seen in tech when Alphabet and Tesla triggered a Nasdaq selloff with record AI spending disclosures just days ago.
TMO shares were up more than 5% in premarket trading on Thursday, erasing the week's earlier losses in one session.
This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any security.
